Post-contrast T-1 weighted MR images are the standard way by which the presence, location, and extent of an enhancing lesion are identified and treatment response monitored. Yet, T1+C images can be confounded by bright pre-contrast T1 signal with only 50-60% agreement among expert readers, when an enhancing ROI must be delineated. As a solution, IB Delta T1 maps provide quantitative images of enhancing lesions that are not confounded by bright pre-contrast T1 signal and the ability to objectively delineate enhancing lesion. dT1 maps have been shown useful for clinical trials and determination of post-surgical extent of resection.
WHAT YOU'LL LEARN
- Delta T1 maps are more than simple difference maps
- Published (multi-center) clinical studies have established the utility and reliability of dT1 maps compared to standard T1+C images.
- Clinical benefits of dT1 for assessing surgical resection extent, quantifying tumor volumes over time, and providing an earlier indication of treatment response
- Practical tips for integration of dT1s into routine clinical workflows
THIS WEBINAR WILL NOT EXCEED 45 MINUTES.
PRESENTED BY
Kathleen Schmainda, PhD
Professor
Kathleen Schmainda is a Professor in the Department of Biophysics & Radiology at the Medical College of Wisconsin (MCW). Her research focuses on the development of MRI methods to assess brain tumor angiogenesis and invasion. Prof Schmainda is a Fellow of the ISMRM and is a recognized leader in the field of quantitative MRI. She has published well over 100 peer-reviewed papers and book chapters, generated 20 inventions, 6 patent applications, 4 issued patents as well as copyrighted software; all stemming from her unique training in the HST program at MIT-Harvard Medical School which focused on clinical translation.
